Evelo Biosciences, Inc. (Nasdaq: EVLO), a biotechnology company, has been awarded U.S. Patent No. US 11,672,834 B2 by The United States Patent and Trademark Office (USPTO).

The patent, titled "Probiotic and prebiotic compositions, and methods of use thereof for modulation of the microbiome," recognizes Evelo Biosciences' innovative work in developing compositions and methods for modulating the microbiome.

In pre-market, $EVLO is currently trading at $0.24, showing a significant increase of +0.16 (+199.03%).

DoubleVerify Holdings, Inc. (NYSE: DV), a leading digital media measurement and analytics platform, received a positive assessment from Needham, maintaining a Buy rating and increasing the price target from $35 to $45. 

Despite closing at $36.97 on Thursday, this upwardly adjusted price target suggests a potential upside of $8.03 or approximately 21.72%, according to the analysis provided by Needham.

Clearfield, Inc. (Nasdaq: CLFD), a trusted provider of fiber management and connectivity solutions, also received favorable attention from Needham, as they maintained a Buy recommendation and raised the price target from $50 to $60. 

With Thursday's closing price of $46.74, the adjusted price target indicates a potential upside of $13.26 or roughly 28.37% for $CLFD, based on the investment banking firm's outlook.

These potential upsides are indicative of the brokerage firm's positive assessment of the companies' future prospects, considering factors such as market trends, financial performance, and growth opportunities. However, it's important to note that these assessments are based on the views of Needham and should be considered alongside other research and analysis when making investment decisions.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)